From 2012 through 2022, rates of drug-resistant infections decreased among hospitalized U.S. patients, with significant variability by pathogen and region.
The AHA has revisited its recommendations for managing blood culture–negative endocarditis in light of new diagnostic approaches such as sequencing of microbial DNA in plasma.